Q-omics provides the consensus-scored DTNBP1 profile across patient tissues and cancer cell-line models. DTNBP1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, DTNBP1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, DTNBP1 protein abundance shows 21,713 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LUAD, KIRC, and PDAC as cancer lineages where DTNBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DTNBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DTNBP1 survival associations across molecular data types. DTNBP1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DTNBP1 RNA expression–survival associations across cancer types. High DTNBP1 expression shows unfavorable associations in KICH, ACC, LGG and MESO, but favorable associations in LUAD and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for DTNBP1 RNA expression.
This table summarizes DTNBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DTNBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DTNBP1 shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, HNSC, COAD and BRCA. The KIRC box plot shows higher DTNBP1 RNA expression in tumor versus normal tissue (log2 FC = +0.718, t-test p < 0.001).
This table shows molecular features associated with DTNBP1 in patient tissues and cancer cell lines. In patient samples, DTNBP1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, DTNBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
